grants_govPA-27-101
Open
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)
- Response deadline
- Apr 5, 2029 Due in 962 days
- Date posted
- May 28, 2026
- Source
- Open notice
Description
The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).
Classifications
- NAICS93.853
Documents (1)
- DownloadPA-27-101-Revised-Full-Announcement.htmltext/html;charset=UTF-8170 KB
Contacts
- seedinfo@nih.gov301-402-2541
Similar contracts
- Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)Due Sep 28, 2026
- Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)Due Dec 2, 2026
- NINDS Child Neurology Career Development Program (CNCDP) (K12 - Clinical Trial Not Allowed)Due Jul 10, 2026
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)Due Nov 10, 2026
- Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)Due Oct 8, 2027
- HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)Due Jul 16, 2026